Koh Hyun Min, Han Nayoung
Department of Pathology, Jeju National University School of Medicine, Jeju, Republic of Korea.
Department of Pathology, Jeju National University Hospital, Jeju, Republic of Korea.
Transl Cancer Res. 2024 Aug 31;13(8):4231-4241. doi: 10.21037/tcr-24-275. Epub 2024 Aug 6.
Tumor necrosis factor receptor 2 (TNFR2) is a subtype of the tumor necrosis factor receptors and is known to promote cancer progression by enhancing cancer cell proliferation and inducing immune suppression. More recently, there are reports that TNFR2 expression is related to the prognosis of patients with cancer, including lung, breast, esophageal, colorectal cancer, and lymphoma. In this study, the correlation between the expression of TNFR2 and the prognosis and clinicopathological factors of cancer was systematically evaluated. This study aimed at elucidating the relationship between TNFR2 and prognosis in patients with cancer.
PubMed, Embase, and Cochrane Library were searched and a meta-analysis was performed to assess the prognostic and clinicopathological values of TNFR2 expression in patients with cancer.
Nine studies with 2,229 patients were included. High expression of TNFR2 was significantly correlated with poor overall survival (OS) [hazard ratio (HR), 1.76; 95% confidence interval (CI): 1.37-2.27; P<0.001] and disease-free survival (DFS) (HR, 2.75; 95% CI: 1.92-3.92; P<0.001). High expression of TNFR2 was also significantly associated with higher tumor grade [odds ratio (OR), 1.58; 95% CI: 1.26-1.98; P<0.001], higher tumor stage (OR, 2.41; 95% CI: 1.62-3.60; P<0.001) and higher clinical stage (OR, 1.80; 95% CI: 1.44-2.23; P<0.001).
High expression of TNFR2 was related to poor prognosis and could be a prognostic factor in patients with cancer.
肿瘤坏死因子受体2（TNFR2）是肿瘤坏死因子受体的一种亚型，已知其通过增强癌细胞增殖和诱导免疫抑制来促进癌症进展。最近，有报道称TNFR2表达与肺癌、乳腺癌、食管癌、结直肠癌和淋巴瘤等癌症患者的预后相关。在本研究中，系统评估了TNFR2表达与癌症预后及临床病理因素之间的相关性。本研究旨在阐明TNFR2与癌症患者预后之间的关系。
检索了PubMed、Embase和Cochrane图书馆，并进行了荟萃分析，以评估TNFR2表达在癌症患者中的预后和临床病理价值。
纳入了9项研究，共2229例患者。TNFR2高表达与总生存期（OS）差显著相关[风险比（HR），1.76；95%置信区间（CI）：1.37-2.27；P<0.001]和无病生存期（DFS）差显著相关（HR，2.75；95%CI：1.92-3.92；P<0.001）。TNFR2高表达还与更高的肿瘤分级[优势比（OR），1.58；95%CI：1.26-1.98；P<0.001]、更高的肿瘤分期（OR，2.41；95%CI：1.62-3.60；P<0.001）和更高的临床分期（OR，1.80；95%CI：1.44-2.23；P<0.001）显著相关。
TNFR2高表达与预后不良相关，可能是癌症患者的一个预后因素。
